Biotech Values

[oc631]

Why should we trust that ACHN has the ability to effectively develop a nuke?

There's a hidden IP roadblock to developing a viable Uridine nucleotide analog. There's a reason the industry continued to focus on guanine nukes over the last couple of years, and shunned Uridine development, even when the red flags were there within the G-class. Now U-nukes are in favor and everyone is extremely nervous about infringement. IDIX has the know-how and the library to be a potential competitor. ACHN does not. It was a fools rally today. ACHN needs to be more creative.